Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL10783749 | 0.78 | MEN1 (0.52) | TSHRCA1CA2MEN1KMT2A | |
| SCHEMBL3421096 | 0.77 | CA1 (0.46) | TSHRTP53SRD5A2CA1CA2 | |
| Terephthalic Acid SCHEMBL7175787 | 0.77 | TSHR (0.75) | TSHRTP53SRD5A2CA1CA2 | |
| Terephthalic Acid SCHEMBL9242726 | 0.74 | TSHR (0.92) | TSHRTP53SRD5A2CA1CA2 | |
| Terephthalic Acid SCHEMBL28157425 | 0.74 | TSHR (0.92) | TSHRTP53SRD5A2CA1CA2 | |
| SCHEMBL4335756 | 0.73 | CA12 (0.40) | CA1CA2MEN1NPC1KMT2A | |
| SCHEMBL2029621 | 0.72 | TSHR (0.67) | TSHRTP53SRD5A2CA1CA2 | |
| SCHEMBL22972761 | 0.72 | TSHR (0.67) | TSHRTP53SRD5A2CA1CA2 | |
| SCHEMBL17040204 | 0.72 | TSHR (0.67) | TSHRTP53SRD5A2CA1CA2 | |
| SCHEMBL915095 | 0.71 | ALDH1A1 (0.41) | TSHRCA1CA2MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009108704-A1 | O-ALKYLATED PI-3 KINASE INHIBITOR PRODRUG COMBINATION | SEMAFORE PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | claimed |
| US-20090011975-A1 | TARGETED BONE MARROW PROTECTION AGENTS | SEMAFORE PHARMACEUTICALS INC. (US) | 2009-01-08 | — | — | US | claimed |
| EP-1615639-A2 | TARGETED BONE MARROW PROTECTION AGENTS | Semafore Pharmaceuticals, Inc. (US) | 2006-01-18 | — | — | EP | claimed |
| EP-1611119-A1 | PI-3 KINASE INHIBITOR PRODRUGS | Semafore Pharmaceuticals, Inc. (US) | 2006-01-04 | — | — | EP | claimed |
| US-6949537-B2 | PI-3 kinase inhibitor prodrugs | SEMAFORE PHARMACEUTICALS, INC. (US) | 2005-09-27 | — | — | US | claimed |
| US-20040242631-A1 | PI-3 kinase inhibitor prodrugs | SIGNALRX PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | claimed |
| WO-2004089925-A1 | PI-3 KINASE INHIBITOR PRODRUGS | SEMAFORE PHARMACEUTICALS, INC. (US) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089356-A2 | TARGETED BONE MARROW PROTECTION AGENTS | SEMAFORE PHARMACEUTICALS INC. (US) | 2004-10-21 | — | — | WO | claimed |
| US-20040198783-A1 | Targeted bone marrow protection agents | SEMAFORE PHARMACEUTICALS INC. | 2004-10-07 | — | — | US | claimed |
| US-20190309039-A1 | CRYPTIC POLYPEPTIDES AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2019-10-10 | — | — | US | disclosed |
| US-10323074-B2 | Cryptic polypeptides and uses thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180215801-A1 | CRYPTIC POLYPEPTIDES AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2018-08-02 | — | — | US | disclosed |
| US-20180170987-A1 | CRYPTIC POLYPEPTIDES AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2018-06-21 | — | — | US | disclosed |
| EP-3250588-A1 | CRYPTIC POLYPEPTIDES AND USES THEREOF | Board of Trustees of Michigan State University (US) | 2017-12-06 | — | — | EP | disclosed |
| US-6949537-B2 | PI-3 kinase inhibitor prodrugs | SEMAFORE PHARMACEUTICALS, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050203173-A1 | PI-3 kinase inhibitor prodrugs | SIGNALRX PHARMACEUTICALS, INC. | 2005-09-15 | — | — | US | disclosed |
| US-20040242631-A1 | PI-3 kinase inhibitor prodrugs | SIGNALRX PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004089925-A1 | PI-3 KINASE INHIBITOR PRODRUGS | SEMAFORE PHARMACEUTICALS, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089345-A1 | BONE TARGETING OF BIODEGRADABLE DRUG-CONTAINING NANOPARTICLES | SEMAFORE PHARMACEUTICALS INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040198783-A1 | Targeted bone marrow protection agents | SEMAFORE PHARMACEUTICALS INC. | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090011975-A1 | TARGETED BONE MARROW PROTECTION AGENTS | APAF1, BST2, MCL1 | TSHR 4135/4885TP53 555/4885SRD5A2 4477/4885 |
| US-20040198783-A1 | Targeted bone marrow protection agents | APAF1, BST2, MCL1 | TSHR 4135/4885TP53 555/4885SRD5A2 4477/4885 |
| US-20050203173-A1 | PI-3 kinase inhibitor prodrugs | PI4KA, PI4KB, PI4K2B | TSHR 3974/4885TP53 937/4885SRD5A2 4788/4885 |
| US-20040242631-A1 | PI-3 kinase inhibitor prodrugs | PI4KA, PI4KB, PI4K2B | TSHR 3974/4885TP53 937/4885SRD5A2 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.